Pfizer scraps daily weight loss pill after liver injury in one patient
Headline from NBC 6 South Florida
The decision to stop developing danuglipron adds to a string of setbacks in the pharmaceutical giant’s bid to win a slice of the booming market for GLP-1s.
NBC 6 South Florida's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
The decision to stop developing danuglipron adds to a string of setbacks in the pharmaceutical giant’s bid to win a slice of the booming market for GLP-1s.
Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury and previous problems with pill versions.
Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing. The drugmaker said Tuesday that
Pfizer Inc. will stop developing an obesity pill that has been closely watched by investors, a severe blow in its efforts to compete with blockbuster weight-loss shots from Novo Nordisk A/S and Eli Lilly & Co.
Pharmaceutical giant Pfizer stopped development of its weight-loss pill, danuglipron, after it discovered that one patient suffered potential liver issues.
Pfizer is ending the development of its potential once-daily pill treatment for obesity after venturing into the biggest and most expensive level of clinical testing. The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a possible dr…
Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.
Pfizer scraps daily weight loss pill after liver injury in one patient | Since Then
